Cohance Lifesciences Limited has informed the Exchange regarding a press release dated August 12, 2025, titled "Press Release".
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cohance Lifesciences announced a ₹230 million investment to build a new cGMP oligonucleotide building block manufacturing facility in Hyderabad, India. The facility will add up to 700 kg of annual GMP capacity for complex oligonucleotide building blocks and will feature ISO Class 8 clean rooms. It will integrate with the company's existing pilot plant, enabling scale-up from R&D to commercial supply, with kilo lab validations already underway and GMP-grade PMO and LNA amidite validations expected to begin in CY26. The company stated that customer engagements are already in progress and audits are planned in coming quarters. This investment follows the recently announced USD 10 million expansion of cGMP bioconjugation capabilities at NJ Bio in the United States, and forms part of Cohance's broader capacity expansion across high-growth therapeutic modalities.
This is a strategic capex announcement that strengthens Cohance's positioning in the fast-growing oligonucleotide therapeutics space. For shareholders, it signals management's commitment to scaling the CDMO business beyond traditional small molecules into next-generation modalities, which could support long-term revenue growth, though near-term financial impact will be limited given the modest ₹230 million size relative to FY25 revenue of ₹26 billion.